2014 Newsroom

Keyword Search
 
2014 | 2013 | 2012
DateTitle 
09/05/14Intrexon Announces Filing of Form S-3 Shelf Registration Statement
GERMANTOWN, Md., Sept. 5, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that, pursuant to the terms of its recent acquisition of Trans Ova Genetics, L.C., an industry-leading provider of bovine reproductive technologies, Intrexon filed a registration statement on Form S-3ASR and prospectus supplement covering the possible resale, from time to time, of shares of Intrexon's common stock received by former shareholders of Trans Ova. About... 
Printer Friendly Version
09/05/14Intrexon Announces the Appointment of Keith Canada as Vice President, UltraVector® Division
BLACKSBURG, Va., Sept. 5, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Keith Canada, Ph.D., as Vice President, UltraVector® Division, effective September 15.  He will report to Chief Operating Officer Krish Krishnan.  Dr. Canada's recruitment coincides with the recent introduction of the BeyondBio™ portal, which further expands the accessibility of Intrexon's UltraVector® platform to its diverse commercial collaborators.... 
Printer Friendly Version
09/02/14Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients
SAN CARLOS, Calif., Sept. 2, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has entered into an Exclusive Channel Collaboration (ECC) with Sanofi Chimie, a wholly owned subsidiary of Sanofi (EURONEXT: SAN and NYSE: SNY) to develop an enhanced production process for a specific family of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi's current manufacturing operations in France. This collaboration will leverage In... 
Printer Friendly Version
08/14/14Intrexon Announces Second Quarter and First Half 2014 Financial Results
GERMANTOWN, Md., Aug. 14, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its second quarter and first half results for 2014.  Business Highlights and Recent Developments: Acquired Trans Ova Genetics, L.C. ("Trans Ova"), an industry-leading provider of bovine reproductive technologies and the largest producer and supplier of bovine embryos in the United States. The combined technologies of Intrexon and Trans Ova should enable a leade... 
Printer Friendly Version
08/12/14Intrexon to Announce First Half and Second Quarter 2014 Results and Host Conference Call on August 14th
GERMANTOWN, Md., Aug. 12, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) today announced it will release first half and second quarter 2014 financial results after the market closes on Thursday, August 14th, 2014.  The Company will host a conference call at 5:30 PM ET to discuss the results and provide a general business update. The conference call may be accessed by dialing 1-877-870-4263 (Domestic US) and 1-412-317-0790 (International) and asking to join the "Intrexon Conference Ca... 
Printer Friendly Version
08/11/14Intrexon Launches Leadership Platform in Bovine Genetics
Completes Acquisition of Trans Ova GERMANTOWN, Md. and SIOUX CENTER, Iowa, Aug. 11, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has completed the acquisition of Trans Ova Genetics, L.C., an industry-leading provider of bovine reproductive technologies.  Trans Ova, as a wholly owned subsidiary of Intrexon, will continue to provide the same level of professional service and dedication to its customers operating under the leadership ... 
Printer Friendly Version
08/04/14Intrexon to Present at Jefferies 2014 Global Industrials Conference
GERMANTOWN, Md., Aug. 4, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that Robert Walsh, Senior Vice President of Intrexon's Energy Sector, will present at the Jefferies 2014 Global Industrials Conference in New York City on Monday, August 11th at 2:30PM ET. The presentation materials will be made available on Intrexon's website in the Investors section. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in s... 
Printer Friendly Version
07/29/14Intrexon Enters into Technology Collaboration to Advance Animal Health Applications
BeyondBio™ Platform Enhances The Design and Engineering Process of Biological Solutions GERMANTOWN, Md., July 29, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, has further enhanced its collaboration with a global animal health company to enable remote access to Intrexon's suite of technologies via its groundbreaking BeyondBio™ platform. Dana Di Ferdinando, Intrexon's Chief Information Officer commented, "We are very pleased to announce this techn... 
Printer Friendly Version
07/22/14ZIOPHARM Announces Expansion of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon and Clinical Program Update
Expansion of synthetic immuno-oncology programs to include chimeric antigen receptor T-cell (CAR-T) therapy Increased applications of RheoSwitch ® platform and its unique capabilities into targeted cellular oncology products Phase I trial utilizing Ad-RTS-IL-12 in Glioblastoma Multiforme expected to launch in 2H2014 BOSTON and GERMANTOWN, Md., July 22, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. ("ZIOPHARM") (Nasdaq: ... 
Printer Friendly Version
07/01/14Intrexon to Acquire Trans Ova Genetics
Trans Ova Platform Combined with Intrexon's Technologies to Advance Cattle Genetics SIOUX CENTER, Iowa and GERMANTOWN, Md., July 1, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has entered into a definitive agreement to acquire Trans Ova Genetics, L.C., an industry-leading provider of bovine reproductive technologies.  Trans Ova's dedication and strong commitment to its customers, which has sustained its outstanding reputation with... 
Printer Friendly Version
06/30/14Intrexon's Industrial Products Division Achieves Bioconversion of Methane to Farnesene
Second Product of Intrexon's Proprietary Bioconversion Platform Following Isobutanol Intrexon's Gas-to-Liquids Approach Significantly More Cost-Efficient Versus Conventional Methods SAN CARLOS, Calif., June 30, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its Industrial Products Division has achieved the bioconversion of methane to farnesene in the lab with its proprietary platform. Farnesene is a key building block chemical for di... 
Printer Friendly Version
05/19/14Intrexon Names Christopher Basta Vice President of Investor Relations
GERMANTOWN, Md., May 19, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Christopher Basta as Vice President of Investor Relations, effective immediately. Mr. Basta will report directly to Chairman and Chief Executive Officer Randal J. Kirk. Mr. Basta brings more than 18 years of financial experience to Intrexon.  Most recently, he was a consultant for DSP Group directing its investor relations initiatives.  Prior to ... 
Printer Friendly Version
05/12/14Intrexon to Present at the 2014 BIO World Congress on Industrial Biotechnology
SAN CARLOS, Calif., May 12, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that Robert Walsh, Senior Vice President of Intrexon's Energy Sector, will present at the BIO World Congress on Industrial Biotechnology in the Natural Gas to Fuels and Chemicals session on Thursday, May 15, at 10:30 a.m. Eastern Daylight Time at the Pennsylvania Convention Center in Philadelphia. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a ... 
Printer Friendly Version
05/07/14Intrexon Announces First Quarter Financial Results
GERMANTOWN, Md., May 7, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its first quarter results for 2014.  First Quarter Highlights Highlights for the first quarter of 2014 include: Net income attributable to Intrexon of $4.1 million, or $0.04 per common share, for the quarter ended March 31, 2014 compared to net loss attributable to Intrexon of $36.3 million for the quarter ended March 31, 2013;  Adjusted EBITDA of $17.6 mill... 
Printer Friendly Version
04/16/14Intrexon Appoints Former Ernst & Young CEO James S. Turley to Board of Directors
GERMANTOWN, Md., April 16, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of James S. Turley to its Board of Directors, effective April 16. Mr. Turley will occupy the board seat vacated by Thomas Reed, Ph.D., Founder and Chief Science Officer of Intrexon.  Dr. Reed will continue to serve as Chief Science Officer. Mr. Turley is the former Chairman and Chief Executive Officer of Ernst & Young.  He led the firm from 200... 
Printer Friendly Version
03/31/14Intrexon Announces Annual Report and Fourth Quarter Financial Results
GERMANTOWN, Md., March 31, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its 2013 annual and fourth quarter results for 2013.  Annual Highlights Highlights for 2013 included: Completion of Intrexon's initial public offering which, after taking into effect the exercise of the underwriters' over-allotment option, resulted in net proceeds to the company of approximately $168.3 million; the initial public offering closed less than... 
Printer Friendly Version
03/27/14Intrexon Forms Energy Collaboration for Gas-to-Liquids Bioconversion
Joint Venture to Generate High-Value Oil Products from Low-Cost Natural Gas SAN CARLOS, Calif., March 27, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the formation of Intrexon Energy Partners (IEP), a joint venture with a select group of external investors, to optimize and scale-up Intrexon's gas-to-liquid (GTL) bioconversion platform for the production of fuels and lubricants.  IEP's first target product is isobutanol for gasolin... 
Printer Friendly Version
03/13/14Intrexon Acquires Laboratory Operations from Codexis and Expands Presence to Europe
Company Increases Bioproduction Capabilities and Capacity SAN CARLOS, Calif., March 13, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has acquired state-of-the-art laboratory operations in Budapest, Hungary from Codexis, Inc., a developer of biocatalysts for the pharmaceutical and complex chemistry industries. The acquisition will expand Intrexon's strain and protein development capabilities, as well as strengthen fermenta... 
Printer Friendly Version
03/11/14Intrexon to Present at the 2014 Barclays Global Healthcare Conference
GERMANTOWN, Md., March 11, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that Krish Krishnan, Chief Operating Officer of Intrexon, will present at the Barclays Global Healthcare Conference on Wednesday, March 12, at 9:30 a.m. Eastern Time at the Loews Hotel in Miami, Florida. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy and... 
Printer Friendly Version
03/10/14Amneal and Intrexon Enter into Exclusive Channel Collaboration to Improve Active Pharmaceutical Ingredient Production
BRIDGEWATER, N.J. and GERMANTOWN, Md., March 10, 2014 /PRNewswire/ -- Amneal Pharmaceuticals LLC, the seventh largest generic drug manufacturer by volume in the U.S., and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the formation of an Exclusive Channel Collaboration (ECC) to develop an improved production process for a complex active pharmaceutical ingredient (API).  The companies will continue to explore other similar opportunities for collaboration in the f... 
Printer Friendly Version
03/07/14Intrexon Completes Acquisition of Medistem
GERMANTOWN, Md. and SAN DIEGO, March 7, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has completed the acquisition of San Diego-based Medistem, Inc. (OTCQB: MEDS), a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult-derived stem cells with properties uniquely suited for therapeutic use with Intrexon's existing suite of synthetic biology technologies. Upon integration of these plat... 
Printer Friendly Version
03/04/14Intrexon Strengthens Leadership to Further Advance Company's Environment Sector
Nir Nimrodi of Thermo Fisher Scientific's Life Technologies Division to join as Senior Vice President GERMANTOWN, Md., March 4, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Nir Nimrodi, currently Vice President and General Manager of Food Safety and Animal Health at Life Technologies, Inc., now part of Thermo Fisher Scientific, to head Intrexon's Environment Sector, reporting to Chairman and Chief Executive Officer ... 
Printer Friendly Version
02/03/14Intrexon to Present at the 2014 BIO CEO & Investor Conference
GERMANTOWN, Md., Feb. 3, 2014 /PRNewswire/ -- Intrexon Corporation, (NYSE: XON), a leader in synthetic biology, announced today that Krish Krishnan, Chief Operating Officer of Intrexon, will present at the BIO CEO & Investor Conference on Monday, Feb. 10, at 9:00 a.m. Eastern Standard Time at the Waldorf Astoria in New York. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy and th... 
Printer Friendly Version
01/13/14Fibrocell Science and Intrexon Expand Collaboration to Include Hypermobility-Type Ehlers-Danlos Syndrome
Growing Pipeline of Protein Replacement Therapies for Rare Connective Tissue Disorders EXTON, Pa. and GERMANTOWN, Md., Jan. 13, 2014 /PRNewswire/ -- Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today an expansion of their Exclusive Channel Collaboration (ECC) to ... 
Printer Friendly Version
01/07/14Intrexon to Present at the 2014 J.P. Morgan Healthcare Conference
GERMANTOWN, Md., Jan. 7, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, will present at the J.P. Morgan Healthcare Conference on Wednesday, January 15, at 1:30 p.m. Pacific Standard Time at the Westin St. Francis in San Francisco. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Hea... 
Printer Friendly Version

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds |

Share Page

X
| E-mail Alerts E-mail Alerts | IR Contacts Contact US | Financial Tear Sheet Financial Tear Sheet